Tesofensine: Risks & Legal Status
Important safety information, risks, and regulatory status
Important Safety Warnings
- Regulatory: Tesofensine is not approved by the FDA, EMA, or other major regulators for any indication as of June 2026. It is not on the FDA bulk substances list. US compounding pharmacies cannot lawfully compound it for human use.
Mitigation: Use only within an authorized clinical trial. Do not purchase from research-chemical vendors for human use.
- Supply quality: Material sold by research-chemical vendors lacks pharmaceutical-grade purity, sterility, identity, and potency assurance. Counterfeit, mislabeled, and contaminated material is plausible.
Mitigation: Avoid research-chemical supply for human use. Pharmacopoeial-grade certificate-of-analysis verification by a major US ISO-17025 lab is not a substitute for the GMP / regulatory pathway absent for this drug.
- Drug interactions / serotonin syndrome: Tesofensine inhibits the serotonin transporter and so combines dangerously with MAOIs, SSRIs, SNRIs, triptans, tramadol, and other serotonergic agents - serotonin syndrome can be fatal.
Mitigation: Full medication review before use; absolute avoidance with MAOIs; avoidance of other serotonergic combinations without specialist input.
- Pregnancy / lactation: No adequate human data on tesofensine use in pregnancy or lactation; animal reproductive toxicity not comprehensively published in peer-reviewed indexed literature.
Mitigation: Avoid in pregnancy and lactation; effective contraception during use is appropriate.
📌TL;DR
- •8 risk categories identified
- •4 high-severity risks
- •Legal status varies by country (6 countries listed)
Risk Assessment
Tesofensine is not approved by the FDA, EMA, or other major regulators for any indication as of June 2026. It is not on the FDA bulk substances list. US compounding pharmacies cannot lawfully compound it for human use.
Mitigation: Use only within an authorized clinical trial. Do not purchase from research-chemical vendors for human use.
Material sold by research-chemical vendors lacks pharmaceutical-grade purity, sterility, identity, and potency assurance. Counterfeit, mislabeled, and contaminated material is plausible.
Mitigation: Avoid research-chemical supply for human use. Pharmacopoeial-grade certificate-of-analysis verification by a major US ISO-17025 lab is not a substitute for the GMP / regulatory pathway absent for this drug.
Tesofensine produces dose-dependent increases in heart rate (mean approximately 7-8 bpm in Phase 2) and modest blood-pressure increases via noradrenergic reuptake inhibition. Unmonitored use carries cardiovascular risk, particularly in those with pre-existing hypertension, arrhythmia, or coronary disease.
Mitigation: Cardiovascular screening before use, blood-pressure and heart-rate monitoring, and avoidance in those with significant cardiovascular disease. The Tesomet combination with metoprolol exists specifically to mitigate this risk.
Monoamine reuptake inhibition can precipitate or worsen insomnia, anxiety, irritability, and mood instability. CNS effects contributed to drop-out in earlier Parkinson's and Alzheimer's programs.
Mitigation: Screening for psychiatric history; avoidance in bipolar disorder and psychotic disorders; monitoring during dose escalation and steady-state build-up.
Tesofensine inhibits the serotonin transporter and so combines dangerously with MAOIs, SSRIs, SNRIs, triptans, tramadol, and other serotonergic agents - serotonin syndrome can be fatal.
Mitigation: Full medication review before use; absolute avoidance with MAOIs; avoidance of other serotonergic combinations without specialist input.
Terminal half-life of approximately 220 hours means effects (and side effects) persist for weeks after the last dose. Steady state takes 4-6 weeks of daily dosing.
Mitigation: Allow long washout (4-6 weeks) before introducing interacting medications; recognize that adverse effects may take weeks to resolve after discontinuation.
DAT-active monoamine reuptake inhibitors are a stimulant-adjacent pharmacological class. Tesofensine's slow onset and long half-life reduce - but do not eliminate - this theoretical concern.
Mitigation: Avoidance in those with substance use disorder involving stimulants; careful monitoring in clinical research settings.
No adequate human data on tesofensine use in pregnancy or lactation; animal reproductive toxicity not comprehensively published in peer-reviewed indexed literature.
Mitigation: Avoid in pregnancy and lactation; effective contraception during use is appropriate.
Risk assessment matrix for Tesofensine
Infographic pending generation
⚠️Important Warnings
- •Not FDA-approved; not legally compoundable by US compounding pharmacies
- •Research-chemical supply is not pharmaceutical grade and is not legal for human use in any major jurisdiction
- •Serotonin syndrome risk with MAOIs, SSRIs, SNRIs, triptans, and other serotonergic drugs - absolute MAOI contraindication
- •Sympathomimetic cardiovascular effects warrant blood-pressure and heart- rate monitoring
- •Long half-life means residual effects persist for weeks after discontinuation
- •No adequate human data in pregnancy or lactation - avoid
- •Mood and sleep effects can be significant - psychiatric screening is appropriate
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Unregulated | Not FDA-approved for any indication. Not a controlled substance under the CSA. Not on the FDA bulk substances list, so cannot legally be compounded by 503A or 503B pharmacies for human use. Sale and possession as a research chemical is not equivalent to legality for human administration. |
| European Union | Unregulated | Not approved by the EMA. No EU-wide controlled-substance scheduling for tesofensine specifically as of June 2026; individual member states may have local rules. |
| Denmark | Unregulated | Origin country (NeuroSearch). Investigational compound; subject to Danish Medicines Agency clinical trial regulations. |
| United Kingdom | Unregulated | Not approved by the MHRA. Investigational only. |
| Australia | Unregulated | Not approved by the TGA. Importation for personal use is restricted. |
| Canada | Unregulated | Not approved by Health Canada. Not legally available for human use. |
Legal status map for Tesofensine
Infographic pending generation
Tesofensine Risks, Warnings, and Legal Status#
Critical Safety Information#
The headline risks for tesofensine are:
- Regulatory status: Not FDA-approved and not legally compoundable. Supply through research-chemical vendors lacks quality assurance.
- Cardiovascular load: Dose-dependent heart-rate elevation and modest blood-pressure increase via noradrenergic activity1. This is the principal safety signal motivating the development of the Tesomet combination with metoprolol2.
- Serotonin syndrome: Combination with MAOIs is absolutely contraindicated. Combination with SSRIs, SNRIs, triptans, tramadol, and other serotonergic agents is hazardous3.
- Long half-life: Approximately 220 hours3 - effects, side effects, and drug-interaction risks persist for weeks after discontinuation.
- Psychiatric effects: Insomnia, mood instability, irritability, and anxiety are real and dose-dependent13.
Risk Categories#
Regulatory and Supply Risk#
Tesofensine is not approved by the FDA, EMA, MHRA, or other major regulators as of June 2026. It is not on the FDA bulk substances list, so US 503A and 503B compounding pharmacies cannot lawfully compound it for human use. Material sold by research-chemical vendors:
- Has no GMP supply-chain assurance
- Has no enforced purity, sterility, identity, or potency standard
- Is not legally usable in humans
- May be counterfeit, mislabeled, or contaminated
Cardiovascular Risk#
Phase 2 monotherapy data showed mean heart-rate increases of approximately 7-8 bpm at higher doses1. In a population with obesity and elevated cardiovascular baseline risk, this is clinically meaningful. The motivation for Tesomet (tesofensine + metoprolol) is specifically to blunt this signal2.
Psychiatric and CNS Risk#
Mood changes, irritability, insomnia, and anxiety are common and dose-dependent3. These effects contributed to drop-out in the Parkinson's and Alzheimer's programs that preceded the obesity work. People with bipolar disorder, psychotic disorders, or significant anxiety disorders should not use this drug outside of carefully monitored research.
Drug-Interaction Risk#
The triple monoamine reuptake inhibition makes tesofensine pharmacologically interactive with a large fraction of common psychiatric and pain medications. MAOI combination is absolutely contraindicated. SSRI / SNRI / triptan / tramadol combinations require specialist input.
Theoretical Abuse-Liability Risk#
DAT inhibition places tesofensine in a stimulant-adjacent pharmacological class. However, its slow onset of action and long terminal half-life make it pharmacokinetically dissimilar to high-abuse-liability stimulants such as cocaine. No clinical abuse-liability signal has emerged from published trials, but real-world post-marketing data are absent.
Legal Status by Country#
| Country | Approval status | Notes |
|---|---|---|
| United States | Not approved (unregulated as a marketed drug) | Not on FDA bulk substances list; cannot be compounded for human use. Not a CSA-scheduled substance as of June 2026. |
| European Union | Not approved | No EU-wide controlled-substance scheduling specific to tesofensine. |
| Denmark | Not approved (investigational) | Origin country (NeuroSearch); subject to Danish Medicines Agency rules. |
| United Kingdom | Not approved | MHRA-unapproved. |
| Australia | Not approved | TGA-unapproved; personal-import restrictions. |
| Canada | Not approved | Health Canada-unapproved. |
"Unregulated as a marketed drug" does not mean legal for human use. It means no marketing authorization exists, and supply outside of authorized clinical trials is not a permitted pathway.
Special Warnings#
- Pregnancy and lactation: Not enough human data; avoid
- Paediatric use: No data; not appropriate outside research
- Older adults: Heightened sensitivity to sympathomimetic and CNS effects; cardiovascular comorbidity makes this group higher risk
- Driving / operating machinery: Insomnia and mood effects could impair function
- Concomitant antidepressants: Risk of serotonin syndrome; do not combine with MAOIs; specialist supervision needed for any other serotonergic combination
References#
Related Reading#
Footnotes#
-
Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9653):1906-1913. PMID: 18950853. DOI: 10.1016/S0140-6736(08)61525-1. ↩ ↩2 ↩3
-
Saniona AB. Tesofensine / Tesomet pipeline. https://saniona.com/pipeline/tesofensine. Accessed June 2026. ↩ ↩2
-
Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Current Opinion in Investigational Drugs. 2009;10(10):1105-1116. PMID: 19777399. ↩ ↩2 ↩3 ↩4
Frequently Asked Questions About Tesofensine
Is Tesofensine a controlled substance?
Tesofensine is not currently scheduled under the US Controlled Substances Act and is not specifically scheduled under most other national controlled-substance schemes as of June 2026. However, not being scheduled is not the same as being legal for human use - it is not FDA-approved and cannot lawfully be compounded for human administration in the United States.
Can a US compounding pharmacy make Tesofensine?
No. Section 503A and 503B compounding requires the active ingredient to be either an FDA-approved drug or on the FDA bulk substances list for 503A pharmacies (or otherwise qualifying for 503B outsourcing facilities). Tesofensine meets neither criterion as of June 2026, so US compounding pharmacies cannot lawfully compound it for human use.
Is Tesofensine sold as a research chemical?
Tesofensine is reportedly offered by some research-chemical vendors, including (per directory user reports) Titan X Research. Material sold this way is not pharmaceutical-grade, has no GMP supply-chain assurance, and is not legal for human use. This directory documents vendors who carry such material but does not endorse human use.
When could Tesofensine be approved?
Saniona's Tesomet program is in late-stage clinical development as of June 2026, but a peer-reviewed Phase 3 readout had not been indexed in PubMed under verifiable identifiers at the time of this writing. Any timeline to FDA approval depends on Phase 3 outcomes, NDA submission, and FDA review - and may also depend on indication-specific filings (general obesity vs hypothalamic obesity vs Prader-Willi syndrome).
Are there special risks compared with GLP-1 obesity drugs?
Yes. Tesofensine's risk profile is dominated by cardiovascular (sympathomimetic), CNS (mood, sleep), and serotonergic drug-interaction risks - all of which are not prominent with GLP-1 receptor agonists such as semaglutide and tirzepatide. Conversely, the GI and pancreatic/gallbladder risks prominent for GLP-1 agonists are less prominent with tesofensine. The two classes are not interchangeable.
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.